Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 tinostamustine in relapsed/refractory hematologic malignancies
NL-OMON52700Phase 1Completed
- Sponsor
- Mundipharma
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tinostamustine in multiple myeloma (MM), Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL) and 5 more (5 arms), sponsored by Mundipharma. Primary endpoints: Objective response rate, Clinical benefit rate and 1 more. Started Jul 2020; status: completed.
02
Drugs
tinostamustine
03
Conditions
multiple myeloma (MM)Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NL-OMON52700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52700.